ライフサイエンスコーパス: hepatitis B vaccine

1 All participants received 3 doses of hepatitis B vaccine.

2 pants were randomized to receive Na-ASP-2 or hepatitis B vaccine.

3 ticipants received 3 doses of plasma-derived hepatitis B vaccine.

4 >/=6 months using 3 doses of plasma-derived hepatitis B vaccine.

5 anti-HBs) received vaccination with standard hepatitis B vaccine.

6 an after the introduction of the recombinant hepatitis B vaccine.

7 Controls received hepatitis B vaccine.

8 omplete nonresponders to currently available hepatitis B vaccines.

9 but concurrent injections of hepatitis A and hepatitis B vaccines.

10 e immunized with 1 of 2 licensed recombinant hepatitis B vaccines.

11 Of the 60 cases, 46 had received hepatitis B vaccines.

12 IU/mL received 1 booster dose of recombinant hepatitis B vaccine 2-4 weeks later and were then evalua

13 patitis C) received 3 doses of a recombinant hepatitis B vaccine, according to a 0-, 1-, and 6-month

14 cine adjuvanted with potassium alum, a human hepatitis B vaccine adjuvanted with aluminum hydroxide,

15 efficacy of immunity induced by a commercial hepatitis B vaccine against a tissue culture-derived, cl

16 To determine the protection afforded by hepatitis B vaccine, Alaska Native persons who had recei

17 out one half of centers routinely administer hepatitis B vaccine and approximately three quarters imm

18 ect of a universal newborn immunization with hepatitis B vaccine and mass population screening immuni

19 ls <10 mIU/mL received 1 dose of recombinant hepatitis B vaccine and were evaluated on the basis of a

20 motif are potentially useful as alternative hepatitis B vaccines and as diagnostic reagents for the

21 relationship between antibody response to a hepatitis-B vaccine and body height, with a positive rel

22 s of age in 1998 received 3 or more doses of hepatitis B vaccine, and 79.9% completed the 4:3:1:3 vac

23 mmended three-dose regimen of plasma-derived hepatitis B vaccine, and 94% demonstrated antibody to he

24 may be associated with impaired responses to hepatitis B vaccine, and evaluation of strategies to imp

25 ptheria-tetanus-acellular pertussis vaccine, hepatitis B vaccine, and in some children Haemophilus in

26 igen genes and responsiveness to measles and hepatitis B vaccines are discussed, along with the influ

27 le sclerosis associated with exposure to the hepatitis B vaccine at any time before the onset of the

28 portion of US infants who received dose 1 of hepatitis B vaccine at birth declined from 47% among tho

29 Administration of the first dose of hepatitis B vaccine at birth is associated with increase

30 ted in September 1999 when preservative-free hepatitis B vaccine became available.

31 Reductions in hepatitis B vaccine birth-dose coverage persisted after

32 Coverage with 3 doses of hepatitis B vaccine by 19 months of age declined from 88

33 sponse to currently available single-antigen hepatitis B vaccines confirmed by measuring hepatitis B

34 In healthy normal adults, a triple antigen hepatitis B vaccine containing S and pre-S antigens prod

35 These data suggest that immunization with hepatitis B vaccine continues to provide high levels of

36 Hepatitis B vaccine coverage was 93% among 567 children

37 Long-lasting protection resulting from hepatitis B vaccine, despite loss of antibody against he

38 ompared with children who received the first hepatitis B vaccine dose within 7 days of birth, odds ra

39 by primary immunization with plasma-derived hepatitis B vaccine during childhood and adulthood lasts

40 by primary immunization with plasma-derived hepatitis B vaccine during childhood and adulthood lasts

41 s in viral genetic diversity as a measure of hepatitis B vaccine effectiveness has major limitations.

42 in all groups (35.5% of all doses), with the hepatitis B vaccine eliciting fewer injection-site sympt

43 les induced by hepatitis A vaccine (Havrix), hepatitis B vaccine (Engerix-B), and hepatitis A and B c

44 rix vaccine) or control vaccine formulation (hepatitis B vaccine FENDrix) and subsequently challenged

45 ated at birth retain immunological memory to hepatitis B vaccine for 15 years, but those who did not

46 types required measles, mumps, rubella, and hepatitis B vaccines for entering students; varicella va

47 Follow-up studies of recipients of hepatitis B vaccine from endemic areas have reported los

48 to each other and to hepatitis A vaccine and hepatitis B vaccine given separately and concurrently wa

49 lmette-Guerin (BCG) vaccine, Triple vaccine, Hepatitis B vaccine (HBV), Polio, Measles, Rubella, Mump

50 A single dose of the new triple-antigen hepatitis B vaccine (Hepacare) produced a successful res

51 teers (18-45 years old) received recombinant hepatitis B vaccine IM at 0, 1, and 6 months and were ra

52 from a cohort vaccinated with plasma-derived hepatitis B vaccine in 1981 who have been followed perio

53 epatitis A vaccine with that of a commercial hepatitis B vaccine in subjects with chronic hepatitis C

54 Hepatitis B vaccine is an effective measure to prevent h

55 antigen (anti-HBc) should be vaccinated with hepatitis B vaccine is not certain.

56 ding health care workers) resulting from the hepatitis B vaccine primary series is unknown.

57 rrent and expanding worldwide application of hepatitis B vaccine promises to eliminate and eventually

58 benefits of hepatitis B immune globulin and hepatitis B vaccine prophylaxis of newborns of hepatitis

59 Hepatitis B vaccine provides a model for improving uptak

60 plasma-derived and yeast-derived recombinant hepatitis B vaccines represents a major contribution to

61 t European and US guidelines for recombinant hepatitis B vaccine (rHBV) after hematopoietic-cell tran

62 Countries welcomed the introduction of hepatitis B vaccine, safe injection equipment, and the f

63 s ratios (ORs) for not completing the 3-dose hepatitis B vaccine series among children who received t

64 and >/=55 years were more likely to initiate hepatitis B vaccine series compared with those aged 18-2

65 ion of chimpanzees with licensed recombinant hepatitis B vaccines stimulates anti-HBs that is broadly

66 onsistency lots of a combination hepatitis A/hepatitis B vaccine to each other and to hepatitis A vac

67 In hepatitis B vaccine trials in Amsterdam, New York City,

68 Present hepatitis B vaccines use multidose prolonged regimens, w

69 The efficacy of 10-microg and 40-microg hepatitis B vaccines was compared with that of an invest

70 t study, the protective efficacy of licensed hepatitis B vaccines was evaluated against challenge wit

71 tive persons who had received plasma-derived hepatitis B vaccine when they were >6 months of age were

72 ad previously completed two 3-dose series of hepatitis B vaccine without achieving a protective level

73 that GM-CSF given intramuscularly (IM) with hepatitis B vaccine would result in increased seroconver